Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

NCT00510874 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

780

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Pumarix™
BIOLOGICAL: Pandemrix ™

Sponsor

GlaxoSmithKline